Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2036-09-30 | Direct | 32,012 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 32,012 · Balance 32,012 F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 3, 2026 00:15 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 32,012 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0001878313-26-000096 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,012 Underlying: Common Stock · 32,012 shares Expires 2036-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 13:03 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 37,595 | $1.32 | $49,516.37 |
DisclosureSEC source: 0001878313-26-000084 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,296 Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 46,620 | $1.35 | $62,937.00 |
DisclosureSEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 3 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,701 Read SEC document |
| August 27, 2026 Filed Sep 1, 2026 20:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 78,239 | $1.39 | $108,752.21 |
DisclosureSEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,081 Read SEC document |
| August 26, 2026 Filed Sep 1, 2026 20:16 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 8,931 | $1.39 | $12,414.09 |
DisclosureSEC source: 0001878313-26-000082 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 610,842 Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 11:56 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,794 | $1.33 | $2,386.02 |
DisclosureSEC source: 0001878313-26-000079 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 601,911 Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:09 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 11,899 | $1.37 | $16,301.63 |
DisclosureSEC source: 0001878313-26-000077 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,117 Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 26,355 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001878313-26-000073 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,355 Underlying: Common Stock · 26,355 shares Expires 2036-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:55 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 27,258 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001878313-26-000037 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,258 Underlying: Common Stock · 27,258 shares Expires 2036-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 13:38 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantOptions · Derivative | 24,060 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001878313-26-000010 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,060 Underlying: Common Stock · 24,060 shares Expires 2035-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| October 02, 2025 Filed Oct 6, 2025 20:23 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,459 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001878313-25-000029 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,459 Underlying: Common Stock · 20,459 shares Expires 2035-10-02 F1 · derivative.exercise_date: The stock options, granted on October 2, 2025, pursuant to the MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:17 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,380 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001127602-25-018658 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,380 Underlying: Common Stock · 20,380 shares Expires 2035-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2025 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 20,000 | $2.05 Strike: $2.05 | $41,000.00 |
DisclosureSEC source: 0001127602-25-013965 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-08 F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on May 8, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 20,000 | $1.50 | $30,000.00 |
DisclosureSEC source: 0001127602-25-013965 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,218 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on May 8, 2025. Read SEC document |
| April 04, 2025 Filed Apr 8, 2025 20:45 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 20,291 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001127602-25-011815 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,291 Underlying: Common Stock · 20,291 shares Expires 2035-04-04 F1 · derivative.exercise_date: The stock options, granted on April 4, 2025 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 33,333 | $1.85 Strike: $1.85 | $61,666.05 |
DisclosureSEC source: 0001127602-25-008330 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires 2031-03-03 F2 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on March 3, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:42 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 33,333 | $1.50 | $49,999.50 |
DisclosureSEC source: 0001127602-25-008330 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 568,218 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on March 3, 2025. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:11 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 73,333 | $1.87 Strike: $1.87 | $137,132.71 |
DisclosureSEC source: 0001127602-25-006578 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,333 Underlying: Common Stock · 73,333 shares Expires 2030-08-24 F2 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 21:11 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 73,333 | $1.50 | $109,999.50 |
DisclosureSEC source: 0001127602-25-006578 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,885 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were isused under the Issuer's 2021 Equity Incentive Plan on February 24, 2024. Read SEC document |
| February 24, 2025 Filed Mar 5, 2025 21:37 UTC Amendment | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 73,333 | $1.87 Strike: $1.87 | $137,132.71 |
DisclosureSEC source: 0001127602-25-008317 · form4a.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,333 Underlying: Common Stock · 73,333 shares Expires 2031-02-25 F2 · security: This Form 4/A is being filed to correct the "Date Exercisable" and "Expiration Date" in Section 6 of Table II reported in the original Form 4 filed on February 25, 2025 as well as to correct the date of the Securities Purchase Agreement orginally referenced in the footnote 1 and 2 to "February 24, 2025". F3 · shares: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on February 24, 2025. The options are exercisable beginning on the one-year anniversary of the issuance date and expire 6-years after the initial issuance date. Read SEC document |
| February 24, 2025 Filed Mar 5, 2025 21:37 UTC Amendment | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 73,333 | $1.50 | $109,999.50 |
DisclosureSEC source: 0001127602-25-008317 · form4a.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 534,885.04 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plna on February 24, 2025. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 10,225 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001127602-25-000406 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,225 Underlying: Common Stock · 10,225 shares Expires 2034-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| December 13, 2024 Filed Dec 13, 2024 22:15 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 53,418 | $2.08 Strike: $2.08 | $111,109.44 |
DisclosureSEC source: 0001127602-24-029380 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,418 Underlying: Common Stock · 53,418 shares Expires 2030-06-13 F2 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on December 13, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| December 13, 2024 Filed Dec 13, 2024 22:15 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 53,418 | $1.87 | $99,998.50 |
DisclosureSEC source: 0001127602-24-029380 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 514,970 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 13, 2024. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:36 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 88,534 | $2.26 Strike: $2.26 | $199,998.31 |
DisclosureSEC source: 0001127602-24-026380 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,534 Underlying: Common Stock · 88,534 shares Expires 2030-05-01 F2 · derivative.exercise_date: These warrants were purchased pursuant to a Securities Purchase Agreement dated and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024. The options are exercisable beginning on the six month anniversary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:36 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 88,534 | $2.51 | $222,220.34 |
DisclosureSEC source: 0001127602-24-026380 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,134.04 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on November 1, 2024. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:52 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 7,232 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001127602-24-024949 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,232 Underlying: Common Stock · 7,232 shares Expires 2034-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of thate date. Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 20:14 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 5,728 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001127602-24-019865 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,728 Underlying: Common Stock · 5,728 shares Expires 2034-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:56 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 9,193 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-24-011887 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,193 Underlying: Common Stock · 9,193 shares Expires 2034-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2024 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:04 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseWarrants · Derivative | 6,928 | $1.30 Strike: $1.30 | $9,006.40 |
DisclosureSEC source: 0001127602-24-010320 · form4.xml · derivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,928 Underlying: Common Stock · 6,928 shares Expires 2029-09-14 F2 · derivative.exercise_date: The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date. Read SEC document |
| March 14, 2024 Filed Mar 15, 2024 23:04 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 6,928 | $1.17 | $8,105.76 |
DisclosureSEC source: 0001127602-24-010320 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,600.04 F1 · shares: The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. Read SEC document |
| December 31, 2023 Filed Jan 4, 2024 02:02 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 15,418 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-24-000648 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,418 Underlying: Common Stock · 15,418 shares Expires 2033-12-31 F1 · derivative.exercise_date: The stock options, granted on December 31, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 20:10 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,378 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-025151 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,378 Underlying: Common Stock · 8,378 shares Expires 2033-09-30 F1 · derivative.exercise_date: The stock options, granted on September 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 12:17 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 8,910 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001127602-23-019774 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,910 Underlying: Common Stock · 8,910 shares Expires 2033-06-30 F1 · derivative.exercise_date: The stock options, granted on June 30, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| May 18, 2023 Filed May 22, 2023 10:49 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,200 | $2.47 | $2,964.00 |
DisclosureSEC source: 0001127602-23-016379 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,672.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.40 to $2.50, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 10:50 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 8,500 | $2.25 | $19,125.00 |
DisclosureSEC source: 0001127602-23-013712 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,472.04 F1 · kind: These shares were purchased by the reporting person in the issuer's follow-on offering, which closed on April 27, 2023. Read SEC document |
| April 18, 2023 Filed Apr 19, 2023 10:55 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,263 | $4.17 | $5,266.71 |
DisclosureSEC source: 0001127602-23-013177 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,972.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.01 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 10:34 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 5,675 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001127602-23-012019 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,675 Underlying: Common Stock · 5,675 shares Expires 2033-03-31 F1 · derivative.exercise_date: The stock options, granted on March 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:27 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,333 | $3.64 | $4,852.12 |
DisclosureSEC source: 0001127602-23-010853 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 301,709.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.55 to $3.70, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 10:27 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 443 | $3.98 | $1,763.14 |
DisclosureSEC source: 0001127602-23-009813 · form4.xml · nonDerivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,376.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.935 to $4.00, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 09, 2023 Filed Mar 13, 2023 10:27 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 1,057 | $3.98 | $4,206.86 |
DisclosureSEC source: 0001127602-23-009813 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,933.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.00, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 11:37 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 871 | $4.25 | $3,701.75 |
DisclosureSEC source: 0001127602-23-009394 · form4.xml · nonDerivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,876.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.22 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 11:37 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 481 | $4.24 | $2,039.44 |
DisclosureSEC source: 0001127602-23-009394 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,005.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.23 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| February 17, 2023 Filed Feb 21, 2023 11:56 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 50 | $4.25 | $212.50 |
DisclosureSEC source: 0001127602-23-006045 · form4.xml · nonDerivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,524.04 F1 · shares: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.24 to $4.25, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the Issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 11:56 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 10 | $4.25 | $42.50 |
DisclosureSEC source: 0001127602-23-006045 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,474.04 F1 · price: The purchases in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Guerrrero that is intended to comply with the Rule 10b5-1(c) promulgated under the Securites Exchange Act of 1934, as amended. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 22:49 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 3,045 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001127602-23-000647 · form4.xml · derivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,045 Underlying: Common Stock · 3,045 shares Expires 2032-12-30 F1 · derivative.exercise_date: The stock options, granted on December 30, 2022 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| September 13, 2022 Filed Sep 13, 2022 22:19 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 8,798.73 | $3.85 | $33,875.11 |
DisclosureSEC source: 0001127602-22-022401 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,464.04 F1 · price: These shares were purchased by the reporting person in the open market for $3.85 per share on September 13, 2022. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 17:46 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 283.31 | $3.97 | $1,124.74 |
DisclosureSEC source: 0001127602-22-021869 · form4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,665.31 F1 · price: These shares were purchased by the reporting person in the open market for $3.97 per share on August 30, 2022. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:29 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0000899243-22-027444 · doc4.xml · nonDerivative · entry 2 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,382 F2 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
| July 28, 2022 Filed Aug 2, 2022 22:29 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 9,000 | $4.00 | $36,000.00 |
DisclosureSEC source: 0000899243-22-027444 · doc4.xml · nonDerivative · entry 1 Guerrero Ramiro · CIK 0001913253 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,382 F1 · kind: These shares were purchased by the reporting person in the open market for $4.00 per share on July 28, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.